Trial Profile
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2020
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Therapeutic Use
- 09 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Jun 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 11 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.